+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

NICE approves trastuzumab emtansine after deal with drug company



NICE approves trastuzumab emtansine after deal with drug company



BMJ 357: J2930




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 060018990

Download citation: RISBibTeXText

PMID: 28623237

DOI: 10.1136/bmj.j2930


Related references

NICE rejects trastuzumab emtansine for use on NHS. BMJ 351: H6837, 2016

Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics 34(7): 673-680, 2017

NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer. Lancet. Oncology 17(2): 143-144, 2016

LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients. Journal of Pharmaceutical and Biomedical Analysis 145: 33-39, 2017

NICE approves trastuzumab for early stage breast cancer. BMJ 332(7555): 1409, 2006

Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate. Bioconjugate Chemistry 25(7): 1223-1232, 2015

Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Research 16(2): 209, 2015

Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1). Bulletin du Cancer 99(12): 1183-1191, 2013

PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. Bioanalysis 5(9): 1025-1040, 2014

Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate. Annals of PharmacoTherapy 48(11): 1484-1493, 2014

Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Clinical Cancer Research 20(1): 15-20, 2014

Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. Journal of Medicinal Chemistry 57(16): 6949-6964, 2016

Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Expert Opinion on Biological Therapy 11(6): 807-819, 2011

Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. Bioanalysis 5(9): 1007-1023, 2014

Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer. Current Opinion in Molecular Therapeutics 12(3): 350-360, 2010